PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

NCT06296706 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT630
EST. COMPLETION2026-06-01

Conditions

Gastric Cancer

Interventions

Docetaxel for injection (Albumin-bound)Taxotere (docetaxel)

Study details

SPONSORCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
START DATE2024-02-27

Related company profiles

CSPC Pharmaceutical Group

1093.HK

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT06296706
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record